Clinical trials: Antidepressant
- Condition Antidepressant
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd
Depression
To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets
To demonstrate the relative bioavailability of Desipramine Hydrochloride tablets.
- Trial name
- NCT00913822
- Testing
- Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories), Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depression
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
To demonstrate the relative bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride capsules under fed and fasted conditions.
- Trial name
- NCT00913952
- Testing
- Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions, Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions, Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sandoz
Healthy
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets under Fasting Conditions.
- Trial name
- NCT00883155
- Testing
- Bupropion HCl 100 mg Tablets (Invamed Inc.), Wellbutrin 100 mg Tablets (Glaxo Wellcome)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depressive Disorder, Major
A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
The purpose of the study is to evaluate the effect of seltorexant, compared to placebo, as an add-on medication to an antidepressant, on next-day driving performance as assessed by the mean difference of standard deviation of…
- Trial name
- NCT04451187
- Testing
- Seltorexant Dose 1, Seltorexant Dose 2, Zopiclone
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Relative Bioavailability Food Effect Study of LY03005
The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.
- Trial name
- NCT03822065
- Testing
- LY03005
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
Depressive Disorder, Major
A Study of GW856553X For the Treatment of Depression
GW856553 is a novel compound, currently in development for the treatment of Major Depressive Disorder (MDD), and other indications.
- Trial name
- NCT00569062
- Testing
- GW856553X
- Where
- 15 sites in Estonia, India and 1 more
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos
Depression
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions
To demonstrate the relative bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride capsules under fasted conditions.
- Trial name
- NCT00913783
- Testing
- Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals), Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depression
To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets
To demonstrate the relative bioavailability of Desipramine Hydrochloride 50 mg tablets.
- Trial name
- NCT00913237
- Testing
- Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories), Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depression
To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets
To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.
- Trial name
- NCT00913419
- Testing
- Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories, Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depression
To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets
To demonstrate the relative bioequivalency of Cord's 100 mg Desipramine HCl tablets to Merrell Dow's 100 mg Norpramin tablets.
- Trial name
- NCT00913809
- Testing
- Desipramine HCL 100 mg Tablets Cord Laboratories, Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depression
To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions
To demonstrate the relative bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg imipramine hydrochloride tablets in healthy adult volunteers under fasting conditions.
- Trial name
- NCT00946764
- Testing
- Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.), Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®.
- Trial name
- NCT01369030
- Testing
- Deplin®
- Where
- 2 sites in United States
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Hepatitis C Virus
TMC435-TiDP16-C112 - Interaction Trial With Antidepressants
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 150mg q.d. (once a day) on the steady-state pharmacokinetics of escitalopram 10 mg q.d., and vice versa.
- Trial name
- NCT01090700
- Testing
- TMC435, Escitalopram, TMC435 + Escitalopram
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depression
To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg
To demonstrate the relative bioavailability of fluoxetine hydrochloride capsules, 40 mg.
- Trial name
- NCT00947076
- Testing
- Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc), Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depression
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the…
- Trial name
- NCT02237937
- Testing
- Paroxetine, Sertraline, Citalopram
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH